Thursday, 5 December 2024
  
Login

Australia's most trusted
source of pharma news

Thursday, 05 December 2024
News

Biosim rushes for $72M market

Posted 2 December 2024 AM

A $72 million market in Australia is being challenged by a biosimilar, following moves overseas.

In November Celltrion had Omlyclo registered on the ARTG. The treatment contains omalizumab, the same active ingredient as in Novartis' Xolair.

To see the whole article, please login

Popular

Disruption coming to Med Affairs
$56M drug hit with first generic
Four PBS listings wrap up 2024
Biosim rushes for $72M market
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home